ClinicalTrials.gg
RecruitingNCT05978388FIBCAGUpdated Jun 26, 2024

Coronary Computed Tomography AngioGraphy Prior to Catheter Ablation in Patients With Atrial FIBrillation

An interventional study of Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation in Atrial Fibrillation, sponsored by Tor Biering-Sørensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Tor Biering-Sørensen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Atrial Fibrillation with a site in Denmark — 31 open to participants now, 48 under way, 3 of them phase 3. Atrial Fibrillation · Denmark.

Planned enrollment
41st of 140
852 · median 273
Started
2024
with 15 others
No phase
73 of 176
18 open now
Primary completion
2028-04
later than 38 of 47 live
Registered
142nd of 176
by date

Among the 176 studies in Atrial Fibrillation with a site in Denmark, this one is the 41st largest by planned enrollment of the 140 interventional ones that give a count, is one of 16 that started in 2024, is one of 73 with no phase, reaches primary completion later than 38 of the 47 other live ones, and was the 142nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

31 of the 176 studies in Atrial Fibrillation with a site in Denmark are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Atrial Fibrillation with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this randomized, controlled trial is to investigate whether coronary computed tomography (CT) angiography prior to catheter ablation and derived treatment (medical anti-ischemic and multimodality treatment and/or mechanical revascularization) can improve clinical outcomes in patients with atrial fibrillation undergoing catheter ablation.

A sub-study will investigate the effect of different ablation strategies on clinical outcomes in patients with atrial fibrillation undergoing catheter ablation.

Read the detailed description

The study is an investigator-initiated, prospective, randomized, unblinded, controlled trial to investigate whether coronary CT angiography prior to catheter ablation and derived treatment can improve clinical outcomes in patients with atrial fibrillation undergoing catheter ablation. The study population will consist of approximately 852 patients aged 18 years and above referred for a catheter ablation treatment for atrial fibrillation at Gentofte Hospital in Denmark. All participants included in the study will have a coronary CT angiography and coronary artery calcium (CAC) scoring performed as an amendment to the standard CT scan of the heart for mapping of the atria prior to catheter ablation. The participants are randomized 1:1 to either have the coronary CT angiography analyzed or not at the time of catheter ablation. According to the results of the coronary CT angiography in the intervention group, subsequent actions may include intensified multimodality medical treatment or referral to further functional imaging or invasive coronary angiography and possibly mechanical revascularization according to clinical guidelines. The study will be completed when each patient has been followed for at least 1 year. After ablation, an insertable cardiac monitor will be implanted in participants to monitor the heart rhythm continuously throughout the study period.The primary endpoint is time to first documented recurrence of atrial tachyarrhythmia lasting >30 seconds between 91 days after ablation and end of follow-up.

All participants meeting the eligibility criteria and enrolled in the FIBCAG main study are eligible to participate in a sub-study with the purpose of investigating different catheter ablation strategies by sub-randomizing participants to different ablation protocols depending on whether they have paroxysmal or persistent atrial fibrillation or they are undergoing first or redo ablation:

  1. If they have paroxysmal atrial fibrillation, the participants will be randomized 1:1 to either pulmonary vein isolation (PVI) or PVI plus posterior wall isolation (FIBCAG-PAF).
  2. If they have persistent atrial fibrillation, the participants will be randomized 1:1 to either PVI or PVI plus posterior wall isolation, mitral isthmus block, cavotricuspid isthmus block and intercaval linear ablation (FIBCAG-PeAF).
  3. If they are undergoing reablation, the participants will be randomized 1:1 to either PVI or PVI plus posterior wall isolation, mitral isthmus block, cavotricuspid isthmus block and intercaval linear ablation (FIBCAG-Redo).

All ablation procedures and strategies are currently standard interventions in clinical care. Procedures are performed under general anesthesia or deep sedation based on availability, and patients are blinded to the method of ablation. PVI will be performed according to best current clinical practice using pulsed field ablation with a single shot device or by point-by-point ablation.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Coronary Artery Disease
  • Coronary Computed Tomography Angiography
  • Atrial Fibrillation
  • Ischemic heart disease
  • Catheter Ablation
  • Atherosclerosis
  • Cardiovascular Diseases
  • Randomized Controlled Trial
  • Statins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years.
  • Referral for catheter ablation treatment (excluding AV-junction ablation) for atrial fibrillation (both paroxysmal and persistent atrial fibrillation) at the Department of Cardiology at Gentofte Hospital. Both first ablation and re-ablation treatments are included.
  • The ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known atherosclerotic cardiovascular disease (ASCVD).
  • Ongoing treatment with statins.
  • for coronary CT angiography, e.g. contrast allergy
  • Recent coronary CT angiography including CAC-score without positive findings \<3 years prior to screening.
  • Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
852 participants (estimated)

Study arms

  • Experimental
    Analysis of coronary CT angiography and CAC scoring at the time of catheter ablation

    Based on the results of the coronary CT angiography and CAC scoring in the intervention group, relevant anti-ischemic and multimodality treatment will be initiated according to clinical guidelines.

    Diagnostic Test: Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation

  • No intervention
    No analysis of coronary CT angiography and CAC scoring at the time of catheter ablation

    Patients in the control group will follow the current standard of care prior to ablation.

Interventions

  • Diagnostic testAnalysis of coronary CT Angiography and CAC scoring at the time of catheter ablation

    Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.

06

What researchers measure

Primary outcomes

  1. Between-group difference in time to first recurrence of atrial tachyarrhythmia lasting >30 seconds between 91 days after ablation and end of follow-up.

    Time frame: Up to 4 years

Secondary outcomes

  1. Between-group difference in time to first documented occurrence of other arrhythmias after ablation

    Time frame: Up to 4 years

  2. Between-group difference in AF burden as registered by the implantable cardiac monitor after ablation

    Time frame: Up to 4 years

  3. Between-group difference in the number of participants hospitalized for angina pectoris or acute coronary syndrome after ablation

    Time frame: Up to 4 years

  4. Between-group difference in the incidence of acute myocardial infarction after ablation

    Time frame: Up to 4 years

  5. Between-group difference in the number of patients undergoing revascularization procedures after ablation

    Time frame: Up to 4 years

  6. Between-group difference in the number of deaths due to cardiovascular disease after ablation

    Time frame: Up to 4 years

  7. Between-group difference in incidence of stroke after ablation

    Time frame: Up to 4 years

  8. Between-group difference in incidence of heart failure or heart failure hospitalization after ablation

    Time frame: Up to 4 years

  9. Between-group difference in number of participants hospitalized for atrial fibrillation or other atrial tachyarrythmias after a 3-month blanking period after ablation

    Time frame: Up to 4 years

  10. Number of cardioversions, repeat ablations, and new-onset antiarrythmic drug treatment after a 3-month blanking period after catheter ablation.

    Time frame: Up to 4 years

Other outcomes

  1. Between-group difference in the prevalence of coronary artery disease in patients with atrial fibrillation at baseline

    Time frame: 0

  2. Between group difference in the quality of life of participants as quantified by a validated self-administered questionnaire

    Time frame: 1 year

  3. The proportion of participants in the active arm that are started or intensified on the following medication following the coronary CT angiography: statins, antithrombotic or antidiabetic medication

    Time frame: 1 month

  4. Between-group differences in the proportion of patients that are started or intensified on the following medication within 1 year after the coronary CT angiography: statins, antithrombotic, antidiabetic, or antihypertensive medication.

    Time frame: 1 year

  5. Between-group difference in the number of patients compliant with their prescribed medication 1 and 2 years after the coronary CT angiography as assessed based on a self-administered questionnaire

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
    Hellerup, Region Hovedstaden 2900, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Please contact the sponsor-investigator in case of any inquiries.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Apr 2028, 48 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 7, 2023
StartActual
Mar 26, 2024
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05978388
Lead sponsor
Tor Biering-Sørensen
Responsible party
Tor Biering-Sørensen (Professor, Head of Center for Translational Cardiology and Pragmatic Randomized Trials, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Aug 7, 2023
Start date
Mar 26, 2024
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Jun 26, 2024

Study contacts

Caroline Espersen, MD
Contact
caroline.espersen@regionh.dk
+4551180082
Tor Biering-Sørensen, MD, PhD, MPH, MSc
Contact
tor.biering-soerensen@regionh.dk
+4528933590
Tor Biering-Sørensen, MD, PhD, MPH, MSc
study chair · Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion